Related references
Note: Only part of the references are listed.Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo
Alexander Schulte et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Growth factor receptor bound protein-7 regulates proliferation, cell cycle, and mitochondrial apoptosis of thyroid cancer cells via MAPK/ERK signaling
Haili Tang et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)
Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies
Inigo Landa et al.
CLINICAL CANCER RESEARCH (2019)
Diagnosis and Management of Anaplastic Thyroid Cancer
Ashish Chintakuntlawar et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2019)
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades
Taisuke Hoshi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
A Phase II study of the safety and efficacy oflenvatinib in patients with advanced thyroidcancer
Shunji Takahashi et al.
FUTURE ONCOLOGY (2019)
IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma
Bowie Y. Cheng et al.
CANCER RESEARCH (2018)
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy
Jack W. Singer et al.
Oncotarget (2018)
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies
Eleonora Molinaro et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells
Kento Kurata et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: A Nationwide Prospective Study
Naoyoshi Onoda et al.
THYROID (2016)
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies
Zhaoyang Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
The Role of IL-1β in the Early Tumor Cell-Induced Angiogenic Response
Yaron Carmi et al.
JOURNAL OF IMMUNOLOGY (2013)
Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro
Jinsong Hu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Augmentation of Therapeutic Responses in Melanoma by Inhibition of IRAK-1,-4
Ratika Srivastava et al.
CANCER RESEARCH (2012)
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Robert C. Smallridge et al.
THYROID (2012)
The Feasibility Study of Docetaxel in Patients with Anaplastic Thyroid Cancer
Kenji Kawada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
DRUG DISCOVERY Inhibitors that activate
Karen Cichowski et al.
NATURE (2010)
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4
JP Powers et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
IL-1 is required for tumor invasiveness and angiogenesis
E Voronov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
